| Summary of Net Revenue, Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales,
depreciation and amortization, operating profit, interest expense,
and income tax (expense) benefit for the three months ended
February 28, 2019 and February 28, 2018:
|
|
|
|
|
|
|
|
|
| |
|
For the three
months
ended February 28,
2019 |
|
|
For the three months
ended February 28,
2018 |
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
7,335,027 |
|
|
$ |
6,200,067 |
|
|
Prepacyte®-CB
|
|
|
25,720 |
|
|
|
28,051 |
|
|
Public cord blood banking
|
|
|
134,365 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total net revenue
|
|
$ |
7,495,112 |
|
|
$ |
6,228,118 |
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
2,038,616 |
|
|
$ |
1,555,323 |
|
|
Prepacyte®-CB
|
|
|
160,006 |
|
|
|
46,185 |
|
|
Public cord blood banking
|
|
|
267,605 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
$ |
2,466,227 |
|
|
$ |
1,601,508 |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
47,917 |
|
|
$ |
27,481 |
|
|
Prepacyte®-CB
|
|
|
9,063 |
|
|
|
9,064 |
|
|
Public cord blood banking
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total depreciation and amortization
|
|
$ |
56,980 |
|
|
$ |
36,545 |
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,130,251 |
|
|
$ |
1,014,336 |
|
|
Prepacyte®-CB
|
|
|
(143,349 |
) |
|
|
(27,199 |
) |
|
Public cord blood banking
|
|
|
(133,240 |
) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total operating income
|
|
$ |
853,662 |
|
|
$ |
987,137 |
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
406,925 |
|
|
$ |
280,977 |
|
|
Prepacyte®-CB
|
|
|
— |
|
|
|
— |
|
|
Public cord blood banking
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$ |
406,925 |
|
|
$ |
280,977 |
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
104,667 |
|
|
$ |
3,202,667 |
|
|
Prepacyte®-CB
|
|
|
— |
|
|
|
— |
|
|
Public cord blood banking
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total income tax expense
|
|
$ |
104,667 |
|
|
$ |
3,202,667 |
|
|
|
|
|
|
|
|
|
|
|
| The following table shows the assets
by segment as of February 28, 2019 and November 30,
2018: |
|
|
|
|
| |
|
As of February 28,
2019 |
|
|
As of November 30,
2018 |
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
27,124,599 |
|
|
$ |
26,239,260 |
|
|
Prepacyte®-CB
|
|
|
307,872 |
|
|
|
319,802 |
|
|
Public cord blood banking
|
|
|
15,909,863 |
|
|
|
15,831,081 |
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$ |
43,342,334 |
|
|
$ |
42,390,143 |
|
|
|
|
|
|
|
|
|
|
|